A study in healthy subjects to assess the pharmacokinetics of savolitinib when administered alone and in combination with rifampicin

Trial Identifier: D5084C00003
Sponsor: AstraZeneca
NCTID:: NCT04118842
Start Date: October 2019
Primary Completion Date: February 2020
Study Completion Date: February 2020
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version

Trial Locations

Country Location
United States of America, MD Baltimore, MD, United States of America, 21225